Wedbush Maintains an 'Underperform' on Gilead Sciences (GILD); Terminates Ambrisentan Phase III Study in IPF; Positive for InterMune
Tweet Send to a Friend
Wedbush maintains an 'Underperform' rating on Gilead Sciences (NASDAQ: GILD), PT $40.
Wedbush analyst says, "Last night, Gilead announced termination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Last night, Gilead announced termination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
